Welcome to our dedicated page for Compugen SEC filings (Ticker: CGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Compugen Ltd. files foreign-issuer reports that document its clinical-stage cancer immunotherapy business, financial results and material corporate developments. Its Form 6-K filings cover quarterly and annual results, interim consolidated financial statements, management discussion and analysis, Inline XBRL financial data, and corporate updates related to programs such as COM701, COM902, rilvegostomig and GS-0321.
The filing record also documents licensing and royalty arrangements, including amendments to the AstraZeneca rilvegostomig agreement, as well as proxy materials, annual general meeting voting results, board composition and registration-statement incorporation matters under Form F-3. These disclosures frame Compugen's capital resources, collaboration economics, governance actions, clinical-development disclosures and foreign private issuer reporting obligations.
Compugen Ltd.’s Chief Operating Officer Pierre Ferre has filed a Form 3 reporting his existing holdings of share options. The filing lists options over a total of 400,000 Ordinary Shares, with exercise prices ranging from 3.0000 to 6.4500 and expiration dates between 2031 and 2035.
One option grant is already fully vested, while others vested or vest 25% on dates in 2023, 2024 and 2025, with the remaining portions vesting in 12 equal quarterly installments, subject to his continued service. A further grant begins vesting 25% on September 30, 2026, then continues in 12 quarterly installments.
Compugen Ltd director Anat Cohen-Dayag has filed an initial ownership report showing existing equity holdings in the company. She holds 108,622 Ordinary Shares directly, including 36,091 restricted stock units (RSUs) that vest in 11 equal quarterly installments beginning on March 31, 2026, subject to continued service.
She also holds multiple share options to buy Ordinary Shares, with exercise prices ranging from $1.02 to $14.40 and expiration dates between 2026 and 2035. This filing records current positions and does not report any new purchases or sales of Compugen shares.
COMPUGEN LTD executive Sharon Kredo Russo, SVP Research & Discovery, filed an initial ownership report showing equity-based compensation rather than any recent share purchases or sales. She holds 19,500 Ordinary Shares in the form of restricted stock units that vest 50% on December 31, 2027, with the remainder vesting in eight equal quarterly installments thereafter, subject to continued service. She also holds a share option covering 26,000 Ordinary Shares at an exercise price of $1.64 per share, expiring November 6, 2035, which vests on the same 50%-then-quarterly schedule, also conditioned on continued service to the company.
Compugen Ltd., an Israel-based immuno-oncology company, reports a 2025 net profit of $35.3 million after years of losses, though it still carries an accumulated deficit of about $453.4 million. The turnaround is driven largely by partnership revenue rather than product sales.
Revenue from collaborations reached roughly $72.8 million in 2025, following $27.9 million in 2024 and $33.5 million in 2023, including a $65 million additional upfront payment from AstraZeneca and substantial upfront and milestone payments from Gilead. Management believes existing cash, deposits and marketable securities can fund operations into 2029, but it still expects future losses and may need more capital.
The company’s near-term outlook rests on four clinical-stage programs—COM701, COM902, GS-0321 and AstraZeneca’s rilvegostomig—and on its Unigen AI/ML discovery platform. The report highlights extensive risks around clinical trial outcomes, patient enrollment, dependence on a small number of partners, manufacturing, competition from advanced modalities such as ADCs and T cell engagers, and the unproven nature of its AI-driven target discovery approach.
Compugen Ltd. reported a sharp turnaround in 2025, moving to net profit and strengthening its balance sheet. For the year ended December 31, 2025, revenue was approximately $72.8 million, up from about $27.9 million in 2024, driven mainly by a $65 million upfront payment from AstraZeneca and payments from a license agreement with Gilead.
The company posted net profit of approximately $35.3 million in 2025, compared with a net loss of about $14.2 million a year earlier. As of December 31, 2025, cash, cash equivalents, short-term deposits and marketable securities totaled roughly $145.6 million, and the company stated it expects this to fund operations into 2029, with no debt.
Management highlighted progress in its immuno-oncology pipeline, including new trials for COM701 in ovarian cancer (MAIA-ovarian) and Phase 1 development of GS-0321 licensed to Gilead, alongside AstraZeneca’s advancement of rilvegostomig in multiple Phase 3 cancer trials.
Compugen Ltd. filed a report describing the appointment of Michele Holcomb, Ph.D. as a new independent director to its Board, effective February 11, 2026. She will serve until immediately after the 2026 annual general meeting or until a successor is elected or her office is vacated earlier.
The company highlights Dr. Holcomb’s more than 30 years of experience across biotech, pharmaceuticals, and healthcare services, including senior roles at Cardinal Health, Teva Pharmaceuticals, and McKinsey & Company, as well as current board positions at PureTech Health, Kimball Electronics, and Controlant.
Compugen Ltd. entered into an amendment with MedImmune Limited, part of the AstraZeneca Group, under which it sold to AstraZeneca a portion of its existing royalty interest in the cancer immunotherapy candidate rilvegostomig for a $65 million upfront payment, due within five business days of the December 16, 2025 amendment date.
The amendment also increases by $25 million the milestone payment payable to Compugen upon the next milestone, defined as the first acceptance of the Biologics License Application for rilvegostomig.
This transaction shifts part of Compugen’s expected future royalty stream into near-term cash while enhancing the potential size of a key future regulatory milestone payment linked to BLA acceptance.
Compugen Ltd. (CGEN) filed a Form 6-K stating it furnished a press release with the company’s third quarter 2025 results as Exhibit 99.1. The filing notes that, with the exception of quotes attributed to Eran Ophir, Ph.D., the press release is incorporated by reference into the company’s effective Form F-3 registration statement (File No. 333-270985).
The report was signed by Eran Ben Dor, General Counsel, on November 10, 2025. Investors seeking financial details should refer to Exhibit 99.1, which contains the full Q3 2025 results.
Compugen Ltd. (CGEN) filed a Form 6-K noting it issued a press release on October 13, 2025, which is furnished as Exhibit 99.1. With the exception of the third, fourth, and fifth paragraphs of the press release, the information incorporated by reference in this report is also incorporated into the Company’s Registration Statement on Form F-3 (File No. 333-270985).
The report was signed by Eran Ben Dor, General Counsel, on October 14, 2025.
Compugen Ltd. reports that it held its 2025 Annual General Meeting of Shareholders on September 16, 2025. According to the company, all proposals presented to shareholders at the meeting were approved by the required majority, meaning each item on the agenda received sufficient support to pass. The notice of meeting, proxy statement and proxy card had previously been filed with the SEC and are incorporated by reference. The company also states that the information in this report is incorporated by reference into its existing shelf registration statement on Form F-3.